Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The expression of miR-107 is down-regulated in AD patients and target genes of miR-107 have been shown to directly involved in AD.
|
31778666 |
2020 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
miR-103 may be a better choice than miR-107 to serve as a potential biomarker for disease risk and disease progression of AD.
|
31420923 |
2020 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to study the miR-107 in Alzheimer's Disease (AD) pathology through regulating SYK and NF-κB signaling pathway.
|
30543171 |
2019 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among the 121 miRNAs 22 were nominally significantly associated with CT and four of them (let-7g-5p, miR-103a-3p, miR-107, and miR-142-3p) also after correction for multiple testing; most of them were previously associated with Alzheimer's disease (AD) or depression.
|
31284290 |
2019 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
LncRNA NEAT1 aggravated Aβ-induced neuronal damage by sponging miR-107, indicating a novel avenue for treatment of AD.
|
31250578 |
2019 |
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Additionally, patients with the onset at 60-69 years of age showed a reduced level of miR-107 (p < 0.05, as compared to AD above 80 years of age).
|
31556571 |
2019 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Of these directionally concordant miRNAs, the strongest evidence was for miR-107 which has also been shown in previous studies to be involved in the dysregulation of proteins involved in aspects of AD pathology, as well as being consistently downregulated in studies of AD brains.
|
29885309 |
2018 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, these results demonstrated that miR‑107 may be a potential target for the treatment of AD.
|
29286086 |
2018 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Then, the expression data of mature-miRNAs (rno-miR-9-5p, rno-miR-29a-3p, rno-miR-106a-5p, rno-miR-107 and rno-miR-125a-3p), which may be effective in AD, were taken with Real-Time PCR.
|
28709849 |
2017 |
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A reduction in whole-blood expression of hsa-miR-9-5p, hsa-miR-106a-5p, hsa-miR-106b-5p, and hsa-miR-107 was significantly associated with an increased risk of AD (p < 0.05).
|
27501295 |
2016 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Only target genes predicted in at least four out of six databases in the case of miR-103 and miR-107 were compared to genes listed in the AlzGene database including genes possibly involved in AD.
|
22594617 |
2012 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
MiR-107 is reduced in Alzheimer's disease brain neocortex: validation study.
|
20413881 |
2010 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
A high-throughput experimental microRNA assay showed that GRN is the strongest target for miR-107 in human H4 neuroglioma cells. miR-107 has been implicated in Alzheimer's disease pathogenesis, and sequence elements in the open reading frame-rather than the 3' untranslated region-of GRN mRNA are recognized by miR-107 and are highly conserved among vertebrate species.
|
20489155 |
2010 |
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BACE1 mRNA levels tended to increase as miR-107 levels decreased in the progression of AD.
|
18234899 |
2008 |